Pfizer (LTS:0Q1N) Accumulated other comprehensive income (loss)

: $-7,961 Mil (As of Dec. 2023)

View and export this data going back to 1967. Start your Free Trial

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Pfizer's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $-7,961 Mil.

Pfizer's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2023 ($-8,102 Mil) to Sep. 2023 ($-7,967 Mil) and increased from Sep. 2023 ($-7,967 Mil) to Dec. 2023 ($-7,961 Mil).

Pfizer's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-5,896 Mil) to Dec. 2022 ($-8,304 Mil) but then increased from Dec. 2022 ($-8,304 Mil) to Dec. 2023 ($-7,961 Mil).

Pfizer Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Pfizer's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

-11,640.00

-5,310.00

-5,896.00

-8,304.00

-7,961.00

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated other comprehensive income (loss)																-8,304.00	-8,289.00	-8,102.00	-7,967.00	-7,961.00

Pfizer Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Pfizer Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Pfizer's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (LTS:0Q1N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (LTS:0Q1N) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (LTS:0Q1N) Headlines

No Headlines